Panakes Fund I

Panakes Partners is an Italy-based venture capital investor founded in 2015, specializing in financing medical companies, startups, and high-growth SMEs in Europe and Israel. The firm offers a broad network of business contacts, domain expertise, proactive portfolio management, and relationships with selected industrial partners. Their investments primarily focus on medical devices, diagnostics, biotech for in-vitro diagnostics, IT healthcare, and medical services within the life-science and healthcare sector. Founded by Alessio Beverina, Fabrizio Landi, and Diana Saraceni, Panakes Partners aims to support innovative companies in the medical field to achieve growth and success.

Andrea Ballerini

Associate

Alessio Beverina

Co-Founder & Managing Partner

Laura Brolis

Chief Financial Officer

Barbara Castellano

Partner

Lorenzo Giordano

CFO

Fabrizio Landi

Founder and Managing Partner

Giacomo Piccinini

Associate

Alessio Piuma

Investment Manager

Diana Saraceni

Co-Founder, Managing Partner

Marco Sardina

Scientific Partner

Robbie Woodman

Partner

27 past transactions

Vivasure Medical

Series C in 2016
Vivasure Medical Limited, a medical device company, engages in the research, development, and manufacture of arterial and venous closure devices based on its patented PerQseal technology. The company develops polymer implants and delivery systems that primarily focused on minimally invasive vessel closures in cardiology, interventional radiology, and vascular surgery areas. Its lead product is an absorbable patch-based large-bore percutaneous closure device that is designed to enable closure of large arteriotomies in transcatheter procedures, such as those used for transcatheter aortic valve replacement (TAVR) and endovascular aneurysm repair (EVAR). Vivasure Medical Limited was incorporated in 2008 and is based in Galway, Ireland.

Seventeen

Series A in 2016
Seventeen is a medtech startup. The company intends to use the funds to finalize the technology and clinically validate it in order to obtain the CE mark.

MMI

Series B in 2022
MMI S.r.l manufactures and develops micro instruments to support surgical interventions at a dimensional scale. The company develops wristed micro instruments and their fabrication process. The company also develops and offers robotic platform. The company's proprietary robotic platform and wristed micro instruments simplifies reconstruction procedures after traumatic injuries and after tumor removal in breast, head, and bones. The company was founded in 2015 and is headquartered in Calci, Italy.

Endostart

Seed Round in 2018
Endostart is a developed a novel proprietary Magnetic Balloon Anchoring Technology.

Echolight

Series A in 2016
Echolight S.r.l., a research based biomed company, develops a non-invasive solution for early diagnosis of osteoporosis. It offers EchoS, an ultrasound device for bone characterization with an approach assessing bone micro-architecture that enables the scanning of central sites. The company was founded in 2011 and is based in Lecce, Italy.

Aileens Pharma

Series A in 2018
The company intends to use the funds to accelerate the development of its platform of topical non-steroidal treatments for atopic dermatitis both in children and adults, as well as other types of dermatological disorders.

SamanTree Medical

Series A in 2019
SamanTree Medical SA, a medical microscopy device company, develops micro-optics based digital microscopy systems with XXL field of view for research, diagnostic, and surgical applications. The company develops a surgical digital microscope that precisely assesses tumor margins by visualizing the cellular structure of the living tissue in real time. Its digital microscope improves surgical treatment decisions and resection accuracy, while reducing the re-operation rates and cutting the overall cost of procedures. The company was incorporated in 2014 and is based in Ecublens, Switzerland.

Alesi Surgical

Venture Round in 2021
Alesi Surgical was founded in 2009 to develop and commercialise products that improve the safety, efficacy and outcomes of surgical procedures. The company is a spin-out from the Welsh Institute for Minimal Access Therapy (WIMAT), a leading surgical training centre in the UK. Alesi Surgical has a unique level of access to experienced surgeons, surgical trainers and trainees, which allows it to identify issues in procedures and design devices to address these issues.

MMI

Series C in 2024
MMI S.r.l manufactures and develops micro instruments to support surgical interventions at a dimensional scale. The company develops wristed micro instruments and their fabrication process. The company also develops and offers robotic platform. The company's proprietary robotic platform and wristed micro instruments simplifies reconstruction procedures after traumatic injuries and after tumor removal in breast, head, and bones. The company was founded in 2015 and is headquartered in Calci, Italy.

Enterprise Therapeutics

Series B in 2024
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases. In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Allotex

Series B in 2023
Allotex, Inc., an ophthalmic biologics and device company, develops contact lens. The company develops allograft corneal inlays and onlays that address all the refractive needs. It develops therapeutic solutions for the treatment of presbyopia, hyperopia, and myopia. The company was incorporated in 2013 and is based in Boston, Massachusetts.

EBAMed

Series A in 2023
EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware and software components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.

CarThera

Series B in 2023
CARTHERA SAS designs and develops therapeutic ultrasound-based medical devices for treating brain disorders. The company’s devices include SONOPROBE, which is used for treatment of brain disorders including brain tumors, epilepsy, metastases, and meningioma and SONOCLOUD, an intracranial ultrasound implant that is used to increase the intracerebral bioavailability of chemotherapy in the treatment of primary brain tumors. The company was founded in 2010 and is headquartered in Paris, France.

MMI

Series A in 2018
MMI S.r.l manufactures and develops micro instruments to support surgical interventions at a dimensional scale. The company develops wristed micro instruments and their fabrication process. The company also develops and offers robotic platform. The company's proprietary robotic platform and wristed micro instruments simplifies reconstruction procedures after traumatic injuries and after tumor removal in breast, head, and bones. The company was founded in 2015 and is headquartered in Calci, Italy.

Vivasure Medical

Series D in 2022
Vivasure Medical Limited, a medical device company, engages in the research, development, and manufacture of arterial and venous closure devices based on its patented PerQseal technology. The company develops polymer implants and delivery systems that primarily focused on minimally invasive vessel closures in cardiology, interventional radiology, and vascular surgery areas. Its lead product is an absorbable patch-based large-bore percutaneous closure device that is designed to enable closure of large arteriotomies in transcatheter procedures, such as those used for transcatheter aortic valve replacement (TAVR) and endovascular aneurysm repair (EVAR). Vivasure Medical Limited was incorporated in 2008 and is based in Galway, Ireland.

Diadem

Venture Round in 2022
Diadem Srl engages in the drug development for Alzheimer’s disease. The company was founded in 2012 and is based in Brescia, Italy.

InnovHeart

Series B in 2020
InnovHeart s.r.l. manufactures transcatheter mitral valve replacement (TMVR) systems for the treatment of mitral valve disease. The company offers Saturn TMVR system a mitral heart valve designed for trans-apical or trans-septal delivery systems. InnovHeart s.r.l. was founded in 2015 and is based in Milan, Italy with an additional office in Newton, Massachusetts.

CarThera

Series B in 2018
CARTHERA SAS designs and develops therapeutic ultrasound-based medical devices for treating brain disorders. The company’s devices include SONOPROBE, which is used for treatment of brain disorders including brain tumors, epilepsy, metastases, and meningioma and SONOCLOUD, an intracranial ultrasound implant that is used to increase the intracerebral bioavailability of chemotherapy in the treatment of primary brain tumors. The company was founded in 2010 and is headquartered in Paris, France.

Neuromod Devices

Series B in 2023
Neuromod Devices Limited, a medical device company, specializes in the research and development of neuromodulation treatments for chronic tinnitus. Its mutebutton is a bi-modal neuromodulation device that focuses on promoting positive therapeutic change in the human nervous system. The company was founded in 2010 and is based in Dublin, Ireland.

Nouscom

Series C in 2023
Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy. The NousCom team is lead by experienced enterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies.

SamanTree Medical

Series B in 2024
SamanTree Medical SA, a medical microscopy device company, develops micro-optics based digital microscopy systems with XXL field of view for research, diagnostic, and surgical applications. The company develops a surgical digital microscope that precisely assesses tumor margins by visualizing the cellular structure of the living tissue in real time. Its digital microscope improves surgical treatment decisions and resection accuracy, while reducing the re-operation rates and cutting the overall cost of procedures. The company was incorporated in 2014 and is based in Ecublens, Switzerland.

InnovHeart

Series C in 2022
InnovHeart s.r.l. manufactures transcatheter mitral valve replacement (TMVR) systems for the treatment of mitral valve disease. The company offers Saturn TMVR system a mitral heart valve designed for trans-apical or trans-septal delivery systems. InnovHeart s.r.l. was founded in 2015 and is based in Milan, Italy with an additional office in Newton, Massachusetts.

Complement Therapeutics

Series A in 2023
Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies.

Salvia BioElectronics

Series A in 2020
Salvia is a young innovative start-up company active in the emerging field of “BioElectronics” that is inspired by biology and electronics to provide innovative therapeutic solutions. The name Salvia is derived from the Latin word salvere, which means "to stay healthy".​They are driven to deliver bioelectronic solutions that restore health for people suffering from severe neurologic disorders; their ambition is to make these novel therapies widely accessible. The Salvia team consists of experienced entrepreneurs, engineers and scientists with diverse professional backgrounds and proven track-record throughout the medical device industry (Sapiens, Medtronic, Philips, St Jude, BioSensors International, Kyphon, etc).